Epkin used Owkin's K Pro to map prostaglandin biology and design the Phase 1 strategy for OKN4395.

PGE2/PGD2 receptor roles and DP1's role in tumor immunity were unclear, making early biomarker and indication choices uncertain. K Pro was used to map pathway crosstalk, define biomarkers and design a Phase 1 trial strategy for OKN4395, now in Phase 1a. The page states hypothesis generation and validation in weeks rather than months and a ranked top four cancer indications.

Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.

This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.